Kintara Therapeutics (KTRA) - Wutah bathi EPS kuartalan

Simbol resmi perusahaan Kintara Therapeutics, Inc. (KTRA)

Kintara Therapeutics revenues are based on future sales of VAL-083 targeted therapy for glioblastoma. Quarterly net income per share dynamics clearly confirm this potential, with the metric currently standing at 29.60. However, liquidity shortages and restructuring are creating financial challenges. Despite this, Kintara Therapeutics maintains its authority among patients through its pursuit of treatment methods for severe brain tumors.

Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Kintara Therapeutics, Inc. (KTRA): kanggo periode 04.07.2022 - 17.11.2026

Rincian analitis perusahaan Kintara Therapeutics

Analisis fundamental perusahaan:kintara.com, KTRA
Produk asil prodhuksi Kintara Pharma

This indicator measures the quarterly dynamics of earnings per share, allowing for a real-time assessment of business model sustainability by comparing revenue and expense growth rates. For Kintara Therapeutics (KTRA), the relative growth of quarterly EPS is critical: success in developing brain cancer drugs will ensure an explosive surge in margins due to low synthesis costs during global sales scaling.

Analisis perusahaan pesaing

Incyte Corporation (INCY) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan HUTCHMED Corp|NUVB (nuvationbio.com) - Wutah bathi EPS kuartalan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan dayonebio.com (DAWN)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan Monopar Corp (MNPR)|INBX - Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan I-Mab Inc. IMAB|Fennec - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|HRTX - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Nuvectis Pharma, Inc.|CHRS: Wutah bathi EPS kuartalan|Wutah bathi resik saben saham sajroning taun lumaku Corbus Pharma CRBP|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan CRDF|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan BeyondSpring Inc. BYSI|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan BCAB (BioAtla Inc)|LIXT (Lixte Biotechnology Holdings, Inc.) - Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan|Citius Pharmaceuticals, Inc. - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan CLRB (Cellectar Biosciences, Inc.)|BioLineRx Corp - Wutah bathi EPS kuartalan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan CANF (Can-Fite BioPharma, Ltd.)|APRE: Wutah bathi EPS kuartalan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Kazia (KZIA)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan silexion.com|NCNA: Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan CMRX|Wutah bathi EPS kuartalan Cyclacel, Inc. (CYCC)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan G1 Therapeutics Inc. GTHX|KRON (Kronos Bio) - Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan|ONCT: Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Portage Biotech Inc